1. Homepage
  2. Equities
  3. Poland
  4. Warsaw Stock Exchange
  5. Mabion S.A.
  6. News
  7. Sector news
    MAB   PLMBION00016

MABION S.A.

(MAB)
  Report
Delayed Warsaw Stock Exchange  -  05/17 11:55:43 am EDT
27.98 PLN   +1.75%
04/21Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
2021MABION S.A.(WSE : MAB) added to S&P Global BMI Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Sector news Bio Therapeutic Drugs
01:28pPfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US
MT
12:41pUBS Adjusts BioNTech Price Target to $168 From $170, Maintains Neutral Rating
MT
11:50aPfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children
MT
11:12aPfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi..
MT
08:55aFDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
08:49aPRESS RELEASE : Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech..
DJ
07:12aVertex Pharmaceuticals Pledges $50 Million to Health Equity
MT
06:08aANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
05:09aPiper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral ..
MT
02:22aWuXi Apptec Eyes Issue of Over 78 Million Shares in Hong Kong Under Mandate
MT
05/16Gilead Sciences Says FDA Lifts Hold on Investigational Lenacapavir to Treat HIV
MT
05/16U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir fo..
CI
05/16Gilead Sciences Says FDA Lifts Clinical Hold On Injectable Lenacapavir
DJ
05/16European ADRs Move Higher in Monday Trading
MT
05/15Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU
MT
05/13UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating
MT
05/11New class of cancer drugs down, not out, after Roche trial setback - analysts
RE
05/11Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
RE
05/11European ADRs Move Sharply Higher in Wednesday Trading
MT
05/11BIONTECH : Goldman Sachs sticks Neutral
MD
05/10TRANSCRIPT : Gilead Sciences, Inc. Presents at Bank of America 2022 Healthcare Conference,..
CI
05/10TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/10Morgan Stanley Lowers BioNTech SE's Price Target to $195 From $197, Equalweight Rating ..
MT
05/10What you need to know about the coronavirus right now
RE
05/09BIONTECH : JP Morgan reiterates its Neutral rating
MD
05/09SECTOR UPDATE : Health Care Stocks Declining Ahead of Monday Close
MT
05/09SECTOR UPDATE : Health Care Stocks Slide with Broader Monday Markets
MT
05/09BioNTech Q1 Results Top Street Estimates; Shares Gain
MT
05/09UBS Adjusts Vertex Pharmaceuticals Price Target to $321 From $322, Maintains Buy Rating
MT
05/09BIONTECH : Jefferies reiterates its Neutral rating
MD
05/09BioNTech Q1 Earnings, Revenue Surge; Shares Rise Pre-Bell
MT
05/09TRANSCRIPT : BioNTech SE, Q1 2022 Earnings Call, May 09, 2022
CI
05/09Equities Slide Pre-Bell as US Signals More Losses; Europe, Asia Retreat
MT
05/09Wall Street Leans Back Pre-Bell; Europe Off, Asia Down
MT
05/09BioNTech Reiterates 2022 Vaccine Revenue Guidance After Boost In Q1 Earnings
MT
05/09COVID vaccine makers shift focus to boosters
RE
05/09Earnings Flash (BNTX) BIONTECH SE Posts Q1 EPS EUR14.24
MT
05/09Earnings Flash (BNTX) BIONTECH SE Posts Q1 Revenue EUR6.38B
MT
05/09BioNTech SE Proposes Special Cash Dividend
CI
05/09BioNTech SE Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/09BioNTech SE Reiterates Earnings Guidance for the Year 2022
CI
05/09BioNTech Revenue, Profit More Than Triple in 1Q; Backs 2022 Outlook
DJ
05/06WuXi AppTec Co., Appoints Minzhang Chen as Director
CI
05/06WuXi AppTec Co Announces Dividend for 2021, Expected Payable Date of H Shareholders Jun..
CI
05/06Goldman Sachs Adjusts Price Target for Vertex Pharmaceuticals to $368 From $329, Mainta..
MT
05/06Wells Fargo Adjusts Vertex Pharmaceuticals' Price Target to $305 From $300, Reiterates ..
MT
05/06Baird Downgrades Vertex Pharmaceuticals to Neutral From Outperform, Adjusts Price Targe..
MT
05/06RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $267 From $274, Keeps Sec..
MT
05/06Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $242 From $249, Maintai..
MT
05/05Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q1 Revenue $2.1B, vs...
MT
1  2  3  4  5  6  7  8  9  10Next